WO1997019722A1 - Apparatus and methods for vibratory intraluminal therapy employing magentostrictive transducers - Google Patents
Apparatus and methods for vibratory intraluminal therapy employing magentostrictive transducers Download PDFInfo
- Publication number
- WO1997019722A1 WO1997019722A1 PCT/US1996/018991 US9618991W WO9719722A1 WO 1997019722 A1 WO1997019722 A1 WO 1997019722A1 US 9618991 W US9618991 W US 9618991W WO 9719722 A1 WO9719722 A1 WO 9719722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- catheter
- energy
- mass
- distal end
- interface
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 19
- 230000002792 vascular Effects 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims description 23
- 239000003527 fibrinolytic agent Substances 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 230000010355 oscillation Effects 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 5
- 229910001279 Dy alloy Inorganic materials 0.000 claims description 4
- 229910000640 Fe alloy Inorganic materials 0.000 claims description 4
- 229910001117 Tb alloy Inorganic materials 0.000 claims description 4
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 206010057469 Vascular stenosis Diseases 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 abstract description 11
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 16
- 208000007536 Thrombosis Diseases 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 8
- 230000002537 thrombolytic effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 210000005166 vasculature Anatomy 0.000 description 7
- 208000037803 restenosis Diseases 0.000 description 6
- 230000002966 stenotic effect Effects 0.000 description 6
- 238000002399 angioplasty Methods 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000005381 magnetic domain Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000000608 laser ablation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- -1 cellular debris Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
- A61B17/2202—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement the ultrasound transducer being inside patient's body at the distal end of the catheter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B06—GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS IN GENERAL
- B06B—METHODS OR APPARATUS FOR GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS OF INFRASONIC, SONIC, OR ULTRASONIC FREQUENCY, e.g. FOR PERFORMING MECHANICAL WORK IN GENERAL
- B06B1/00—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency
- B06B1/02—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy
- B06B1/08—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy operating with magnetostriction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
- A61B17/2202—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement the ultrasound transducer being inside patient's body at the distal end of the catheter
- A61B2017/22021—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement the ultrasound transducer being inside patient's body at the distal end of the catheter electric leads passing through the catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22038—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with a guide wire
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
- A61B2017/22084—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance stone- or thrombus-dissolving
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2217/00—General characteristics of surgical instruments
- A61B2217/002—Auxiliary appliance
- A61B2217/007—Auxiliary appliance with irrigation system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0279—Cannula; Nozzles; Tips; their connection means
Definitions
- the present invention relates generally to medical devices and methods. More particularly, the present invention relates to apparatus and methods for the localized delivery of therapeutic vibratory energy within the vasculature and other body lumens
- vascular diseases such as acute myocardial infarction (heart attack) and peripheral arterial thrombosis (blood clots m leg arteries)
- acute myocardial infarction heart attack
- peripheral arterial thrombosis blood clots m leg arteries
- Current methods of treatment often expensive, are not always effective.
- the cost of treatment and support and the loss of productivity due to vascular diseases together exceed $40 billion per year.
- the core of the problem is that diseased sites within the blood vessels narrow and eventually become completely blocked as a result of the deposition of fatty materials, cellular debris, calcium, and/or blood clots, thereby blocking the vital flow of blood.
- Current treatments include drugs, interventional devices, and/or bypass surgery.
- thrombolytics clot-dissolving drugs
- thrombolytics can also dissolve beneficial clots or injure healthy tissue causing potentially fatal bleeding complications.
- interventional devices including angioplasty, atherectomy, and laser ablation catheters
- the use of such devices to remove obstructing deposits may leave behind a wound that heals by forming a scar
- the scar itself may eventually become a serious obstruction in the blood vessel (a process known as restenosis) .
- interventional devices sometimes develop vasoconstriction (elastic recoil) , a process by which spasms or abrupt reclosures of the vessel occur, thereby restricting the flow of blood and necessitating further intervention.
- bypass surgery can redirect blood around the obstructed artery resulting in improved blood flow.
- the resulting bypass grafts can themselves develop scar tissue and new blood clots in five to ten years resulting in blockage and the need for further treatment.
- all current therapies have limited long term success.
- ultrasonic energy has been proposed both to mechanically disrupt clot and to enhance the intravascular delivery of drugs to dissolve clot and inhibit restenosis.
- Ultrasonic energy may be delivered intravascularly using specialized catheters having an ultrasonically vibrating surface at or near their distal ends.
- One type of ultrasonic catheter employs a wire or other axial transmission element to deliver energy from an ultrasonic energy vibration source located outside the patient, through the catheter, and to the ultrasonically vibrating surface. While such systems can deliver relatively large amounts of energy, the need to transmit that energy through the entire length of the catheter presents a substantial risk to the patient.
- catheters are typically rigid and cannot easily traverse narrow, tortuous arteries, such as the coronary arteries which frequently need to be treated. Because of their rigidity and inability to follow the vascular lumen, these catheters present a serious risk of vascular wall perforation.
- catheters having ultrasonic transducers mounted directly on their distal ends have also been proposed. See, for example, U.S. Patent Nos. 5,362,309; 5,318,014; 5,315,998; 5,269,291; and 5,197,946. By providing the transducer within the catheter itself, there is no need to employ a transmission element along the entire length of the catheter.
- ultrasonic energy is useful for a variety of purposes, including the direct mechanical disruption of clot, the enhancement of thrombolytic activity of agents to dissolve clot, and the enhancement of pharmacologic activity of agents to prevent restenosis of vascular sites previously treated by angioplasty or other interventional methods.
- a rigid ultrasonic probe intended for treating vascular plaque and having fluid delivery means is described in U.S. Patent No. 3,433,226.
- An ultrasonic transmission wire intended for intravascular treatment is described in U.S. Patent No. 5,163,421 and Rosenschein et al. (1990) JACC 15:711-717.
- Ultrasonically assisted atherectomy catheters are described in U.S. Patent 5,085,662 and EP 189329.
- Ultrasonic enhancement of systemic and localized drug delivery is described in U.S. Patent Nos. 5,286,254; 5,282,785; 5,267,985; and 4,948,587; in WO 94/05361 and WO 91/19529; in JP 3-63041; and Yu ita et al .
- an energy- transmitting catheter comprises a catheter body having a proximal end and a distal end.
- a magnetostrictive driver is disposed near the distal end of the catheter body, and an interface surface is mechanically coupled to the driver so that the surface can be oscillated relative to the catheter body in order to radiate vibratory energy into a fluid environment surrounding the catheter.
- the magnetostrictive driver typically comprises a linear element composed of a magnetostrictive material, such as a polycrystalline alloy of terbium, dysprosium, and iron, and a coil disposed coaxially about the linear element. The coil is disposed to provide a magnetic field parallel to the longitudinal direction of the linear element.
- the linear element With increasing magnetic field strength, more magnetic domains change their alignment from random to parallel to the magnetic field, increasing the length of the linear element in direct proportion to the magnetic field strength. This realignment continues until all domains are parallel to the magnetic field, in which case, saturation has occurred.
- a periodically reversing magnetic field will be induced in the linear element, causing the linear element to longitudinally oscillate at a frequency twice the frequency of the driving current.
- the linear element could be driven by combination of permanent magnets and an alternating field, or an alternating field with an offset, to produce magnetic fields of varying amplitude in one direction only. In this case, the magnetic domains are aligned parallel to the field only once during a cycle, producing longitudinal oscillations at the same frequency as that of the driving current.
- the linear element of the magnetostrictive driver is a tube or a solid rod having a length in the range from 3 mm to 12 mm and a diameter in the range from 0.5 mm to 3 mm.
- the linear element will have a particular geometry and composition which permits oscillation at a desired drive frequency, determined by the frequency of the drive current, as just set forth.
- the magnetostrictive driver will be included in a spring-mass assembly which further comprises a tail mass at or near the distal end of the catheter body and a spring element attaching the interface surface to the tail mass.
- the resonant frequency of the interface member and spring element is independent of the tail mass and defined primarily by the mass of the interface member and the elastic modulus of the spring and magnetostrictive elements.
- the resonant system defined by the interface member, the spring element, and the magnetostrictive element can be resonantly driven to enhance both the displacement amplitude of an interface surface on the interface member and increase the efficiency of operation, i.e., the conversion of electrical energy to mechanical energy.
- the spring element preferably comprises an axial member capable of mechanically coupling the interface member to the tail mass with sufficient space therebetween to receive the magnetostrictive driver.
- the spring element will comprise at least one rod secured at a proximal end to the tail mass and at a distal end to the interface member.
- the rod may optionally be tubular to provide the path for a guidewire, infusion of therapeutic agent, or the like.
- a single rod or tube will usually be disposed coaxially within the catheter. Multiple rods or tubes may be disposed symmetrically about the axis of the catheter body.
- the spring element may comprise a thin-walled cylindrical member secured to the tail mass and the interface member and enclosing the magnetostrictive driver in a concentric manner.
- the interface member will usually include at least a distally disposed interface surface which forwardly transmits longitudinal oscillations into the environment surrounding the distal end of the catheter.
- a forwardly disposed interface surface will typically be convex, although it could be flat, concave, or irregular. Additionally, at least a portion of the interface surface may extend laterally over an axial surface of the member.
- a method for treating intraluminal lesions or other target sites comprises providing a catheter having a magnetostrictive driver mechanically coupled to an interface surface at its distal end.
- a distal end of the catheter is advanced to a region near the target site, typically to a region of vascular stenosis within a patient's vasculature, and the interface surface is oscillated by the magnetostrictive driver.
- the interface surface is typically driven at a frequency in the range from 10 kHz to 300 kHz, and will have a longitudinal amplitude in the range from about 0.05 ⁇ m to 40 ⁇ m, preferably from 10 ⁇ m to 25 ⁇ m.
- the forwardly disposed surface of the interface member will typically have an area in the range from 0.5 mm 2 to 20 mm 2 , preferably from 1 mm 2 to 12 mm 2 , and the catheter may be used in a variety of specific therapeutic protocols.
- the interface member will be engaged directly against a vascular obstruction and used to ablate the structure by mechanical vibration and shearing or optionally to dissolve the structure with the simultaneous delivery of a thrombolytic or fibrinolytic agent.
- the catheter can be used to deliver vibratory energy into an environment where a thrombolytic or fibrinolytic agent has been delivered, where the catheter need not be directly engaged against clot or other stenoses. In such cases, the vibratory energy will enhance the activity of the therapeutic agent, typically by improving penetration of the agent into the clot.
- the catheter may be used to deliver an anti-thrombotic agent to a previously treated vascular site to inhibit restenosis. Again, the vibratory energy will typically provide for enhanced delivery and penetration of the anti-thrombotic agent into the blood vessel wall.
- Fig. 1 illustrates an exemplary catheter incorporating a magnetostrictive driver constructed in accordance with the principles of the present invention.
- Fig. 2 is a detailed view of the distal end of the catheter of Fig. 1, shown in partial section.
- Fig. 3 is a cross-sectional view taken along line 3- 3 of Fig. 2.
- Fig. 4 is an alternative detailed view of the distal end of the catheter of Fig. 1, shown in partial section.
- Fig. 5 is a cross-sectional view taken along line 5-
- Fig. 6 illustrates the use of the catheter of Fig. 1 in a first protocol for ablating clot by direct engagement of an interface surface on the catheter of Fig. 1 with the clot.
- Fig. 7 illustrates the use of the catheter of Fig. 1 in a second protocol for enhancing the activity of the therapeutic agent released from the catheter by imparting vibratory energy into the environment surrounding the catheter using the interface surface.
- the present invention provides apparatus and methods for the treatment of luminal conditions, particularly for the treatment of diseases of the coronary and peripheral vasculature.
- Specific conditions include coronary and peripheral arterial disease and thrombosis.
- the apparatus and methods are useful for primary treatment of such diseases, where the purpose is to ablate, dissolve, or otherwise disrupt the clot, plaque, or other stenotic lesions which are responsible for the disease.
- catheters constructed according to the principles of the present invention can be used to directly engage and transmit vibratory, usually ultrasonic, energy into the stenotic material in order to mechanically disrupt the material to open the associated blood vessel lumen. Such mechanical disruption can be accomplished with or without the simultaneous administration of pharmacologic and therapeutic agents.
- the apparatus and methods of the present invention are also useful to enhance the administration of therapeutic agents, where the therapeutic agents are primarily responsible for the disruption of the stenotic material.
- the catheter may be engaged against the stenotic material, or alternatively may be maintained a short distance away from the stenotic material.
- the vibratory energy will be relied on to agitate and promote the penetration of the therapeutic agent into the stenotic material.
- Suitable therapeutic agents include known thrombolytic and fibrinolytic drugs, such as heparin, tissue plasminogen activator (tPA) , urokinase, streptokinase, and the like.
- the catheters and methods of the present invention are still further useful for the treatment of vascular sites which have been previously treated by other interventional techniques, such as angioplasty, atherectomy, laser ablation, and the like.
- the catheters will be used to agitate and promote the penetration of anti- thrombogenic agents into the vascular or other luminal wall to inhibit restenosis.
- Suitable anti-thrombogenic agents include hirudin, hirulog, heparin, tPA, urokinase, streptokinase, and the like.
- the present invention may also be used for systemic and localized delivery of drugs within other body lumens, such as the ureter, the urethra, fallopian tubes, and the like.
- the present invention may further be used for the systemic and localized delivery of drugs within the vascular system for treatment of non-vascular diseases, e.g., for the treatment of tumors by the localized delivery of drugs to the vasculature supporting the tumor.
- the catheter of the present invention will comprise a catheter body having a proximal end and distal end.
- the catheter body will have dimensions and physical characteristics selected for the particular use.
- the length of the catheter body will typically be from 50 cm to 200 cm, usually being from 75 cm to 150 cm, and the diameter will be from 1 mm to 5 mm, usually being from 2 mm to 4 mm.
- the diameter of the catheter body may vary over its length, and different portions of the length may be formed from different materials.
- the catheter body will comprise a single extrusion having at least one lumen therethrough.
- the lumen will usually be capable of receiving a guidewire, and may also be capable of delivering therapeutic agents and/or carrying electrical wires for connection from the proximal end of the catheter body to the distal end.
- the catheter body may include separate lumens for delivering therapeutic agent (s) , routing electrical wires for connection to the ultrasonic transducer, or other purposes.
- the catheter body may be reinforced over all or a portion of its length. Conventional reinforcement materials include wire braids, wire meshes, wire coils, and the like. When employed with a guidewire for placement within the vasculature, the catheter body may have an "over-the-wire" design or a "rapid exchange" design.
- the guidewire lumen will extend substantially through the entire length of the catheter body.
- the guidewire lumen will terminate in a proximal guidewire port located relatively near the distal end of the catheter body, usually within 50 cm, more usually within 30 cm, and often within 25 cm or less.
- a proximal housing will be secured to the proximal end of the catheter body, where the housing includes a guidewire port, a therapeutic agent infusion port, an electrical connector, and the like.
- a longitudinally vibrating assembly is secured at or near the distal end of the catheter body.
- the assembly will include at least one interface surface, usually present on an interface member, which is vibrated at a desired frequency, wherein the interface surface is oriented to transmit vibrations to the fluid environment surrounding the distal end of the catheter.
- the vibrating assembly will usually be attached directly to the distal end of the catheter body but also could be disposed partially or totally within the distal end of the catheter body.
- the vibrating assembly will have a relatively short length, typically being below 2 cm, preferably being below 1 cm, and typically being in the range from about 0.4 cm to 1.5 cm, more usually in the range from about 0.6 cm to 1 cm.
- the assembly will preferably have a low profile (narrow diameter) to facilitate vascular or other intraluminal introductions, typically having a diameter below 6 mm, usually in the range from 1 mm to 5 mm, more usually in the range from 2 mm to 4 mm.
- the interface surface will be forwardly disposed so that the surface may engage intraluminal obstructions as the catheter is advanced through the body lumen, such as a blood vessel.
- Such forwardly disposed vibrating surfaces will also be useful for projecting ultrasonic energy forwardly to agitate and promote absorption of a liquid therapeutic agent, which agent is usually delivered by the same catheter.
- the interface surfaces may be laterally disposed to radiate ultrasonic energy radially outward from the catheter body.
- the vibrating assembly of the present invention will usually be incorporated in a resonant spring-mass assembly which further comprises a tail mass and a spring element connecting the interface member to the tail mass.
- a magnetostrictive driver (as described more fully below) is disposed between the tail mass and the interface member.
- the mass of the tail mass will be substantially greater than that of the interface member, typically being at least four-fold greater, and usually being at least eight-fold greater.
- the mass of the tail mass will be in the range from about 0.1 gm to 10 gm, more usually in the range from about 0.2 gm to 4 gm.
- the mass of the interface member will be in the range from 0.005 gm to 1 gm, more usually in the range from 0.03 gm to 0.1 gm. In this way, the tail mass will remain substantially stationary or immobilized while the longitudinally oscillating driver imparts longitudinal (axial) movement to the interface member.
- the mass of the interface member and the elastic modulus of the spring element will be selected so that, when combined with the elastic modulus and other characteristics of the longitudinally oscillating driver, the resonantly vibrating assembly will resonate at a particular ultrasonic frequency, typically in the range from 10 kHz to 300 kHz, preferably from 20 kHz to 80 kHz.
- the longitudinally oscillating driver when electronically driven will drive the resonantly vibrating assembly at its resonant frequency, thus enhancing the efficiency of energy transfer and increasing the amplitude of vibration (displacement) of the interface member.
- the interface member will operate with a displacement (under loaded conditions) of at least about 0.5 ⁇ m, preferably in the range from 0.05 ⁇ m to 40 ⁇ m, and more preferably in the range from 10 ⁇ m to 25 ⁇ m.
- the tail mass will usually be formed separately from the catheter body and other components of the vibratory assembly, but optionally could be formed as part of the catheter body or alternatively as an integral unit with the spring element and/or interface member.
- the dimensions and shape of the tail mass will usually be selected to conform to the dimensions of the catheter body, i.e., usually being a short cylinder having a diameter which is the same as or slightly smaller than that of the distal end of the catheter body.
- the interface member will usually form the distal- most tip of the catheter, and will usually have a forwardly disposed convex surface which defines the interface surface.
- the interface surface need not be convex, and could alternatively be concave, flat, irregular, or have any other geometry capable of radiating ultrasonic energy forwardly as the interface member is vibrated.
- the interface surface will have an area in the range from 0.5 mm 2 to 20 mm 2 , preferably from 3 mm 2 to 12 mm 2 .
- the spring element may comprise a single rod or tube extending distally from the tail mass and attached to the proximal surface of the interface member.
- a the single spring element will be disposed coaxially within the catheter.
- the spring element may comprise multiple rods or shafts, in which case they will usually be disposed symmetrically about the axis of the catheter.
- One or more axial passages may be formed through the resonantly vibrating assembly, typically for passage of a guidewire, delivery of therapeutic agents, or the like. To provide such lumens, it will be necessary to form holes through both the tail mass and the interface member. Such holes can be aligned and joined by one or more axial components of the spring element, typically in the form of hollow tubes to provide a continuous lumen through the assembly. Alternatively, axial passages may be formed directly through the longitudinally oscillating driver.
- the present invention will employ a magnetostrictive driver for oscillating the interface surface of the catheter.
- the magnetostrictive driver will generally be oriented to vibrate the interface surface on an interface member in the longitudinal or axial direction relative to the catheter body.
- the interface surface itself may be disposed on the interface member in a variety of orientations, but will usually be disposed laterally over a distal end of the catheter in order to transmit longitudinal oscillations into a fluid environment surrounding the distal end of the catheter.
- at least a portion of the interface surface may be disposed axially over a lateral surface of the catheter body in order to impart transverse vibrations in a radial direction from the catheter body. (See wave lines 93 in Fig. 7) .
- magnetostrictors for use as the magnetostrictive drivers in the catheters of the present invention are described generally in references, such as "Magnetostriction: Theory and Applications of
- the magnetostrictive drivers of the present invention will include at least one linear element having an axis parallel to, and usually coaxial with, the central axis of the catheter body.
- the linear element will be composed of a "magnetostrictive" material, i.e., a material which oscillates in a direction parallel to an applied magnetic field.
- the most common material presently available is a polycrystalline alloy of terbium, dysprosium, and iron (Tb 027 Dy 0 73 Fe 2 ) .
- Magnetostrictors are driven by applying a magnetic field parallel to the expansion axis of the linear element.
- the magnetic field must be uniform over the entire length of the linear element, and magnetic field intensities in the range from 200 to 1200 Oerstads will typically be employed. The higher the intensity of the magnetic field, the greater the expansion, with expansions in the range from 0.1% to 0.2% presently being attainable.
- the linear element of the magnetostrictor may also be placed under compressive forces in a direction parallel to the expansion axis of the material. Typical compressive forces will be in the range from 1 to 4kPSI, preferably from 1.5 to 2.5kPSI.
- the magnetostrictor expands and contracts in length as a result of the application and cessation of a magnetic field parallel to the direction of expansion.
- the expansion results from the alignment of magnetic domains within the material when the magnetic field is present. If the field is reversed, the magnetic domains reverse, again causing expansion of the material.
- the linear element of the magnetostrictor of the present invention will expand and contract at a frequency twice that of the frequency of the field.
- biasing a magnetic field to provide only positive (or negative) components, the linear element could be driven at a frequency equal to that of the frequency of the field.
- the biased magnetic field may be achieved by either the combination of permanent magnetic and an alternating magnetic field of by the electrical bias to the alternating current driving the magnetic field coils.
- the linear element of the magnetostrictor will be driven by an electrically conductive coil disposed about the linear element.
- An alternating magnetic field can then be induced by applying an alternating current to the coil in a conventional manner.
- the magnetic strength will be directly dependent on the design of the magnetic coil surrounding the magnetorestricive element.
- a coil of 80 turns with a length of one centimeter and a current of two amps will have a field strength of typically 200 Oerstads.
- the peak applied current will be in the range from 0.5 to 10A, preferably from 1 to 3A.
- the coil will preferably extend beyond the proximal and distal ends of the linear element of the driver in order to assure uniformity of the applied magnetic field.
- the magnetostrictive linear element be axially compressed in order to achieve maximum displacement.
- Such axial compression will usually be achieved by a linear spring element having flanges or other members for engaging the proximal and distal ends of the linear driving element and applying a constant axial compression.
- the spring element and flanges or other constraining means will be provided by a resonant assembly including a tail mass and the interface member, which are disposed on the proximal and distal sides of the linear driving element, respectively.
- a resonant assembly including a tail mass and the interface member, which are disposed on the proximal and distal sides of the linear driving element, respectively.
- the dimensions of the linear element of the magnetostrictor will be chosen to be compatible with the dimensions of the catheter.
- the linear element will have a length in the range from 3 mm to 12 mm, preferably from 4 mm to 6 mm.
- the diameter will typically be in the range from 0.5 mm to 3 mm, preferably from 1 mm to 2 mm.
- the linear element will be in the form of a tube having the outer dimension ⁇ set forth above and an inner lumen having a diameter in the range from 1 mm to 1.5 mm.
- the lumen will provide for placement of the spring element, an infusion path for therapeutic and pharmacologic agents, and/or a guidewire lumen.
- the spring element which joins the interface member to the tail mass may comprise a single component, e.g., a single solid rod or hollow tube disposed along the longitudinal axis of the catheter or a cylindrical shell either within or external to the longitudinally oscillating driver.
- the spring element may comprise a plurality of components, such as a plurality of rods or tubes disposed symmetrically about the longitudinal axis of the catheter.
- the spring element may be composed of any of a wide variety of materials, most typically being a non-magnetic stainless steel, such as a hardened stainles ⁇ steel having a Rockwell stiffness of at least about 35.
- the cross-sectional area of the spring element (s) shall be sufficient to provide a maximum tension of approximately 20% of the tensile strength of the material, typically about 25,000 PSI, at the time when the spring experiences its maximum deformation, i.e., the time of maximum forward displacement of the interface member.
- the assembly of the tail mass, interface member, and longitudinally oscillating driver is compressed by the spring mass with a static force sufficient to present continuing compressive forces at the time when the assembly shrinks to its minimum longitudinal displacement.
- the interface member and spring mass shall have a mass and stiffnes ⁇ which together assure that the spring element retains compressive force on the interface member at the time of maximum reverse acceleration in order to prevent the interface mass from separating from the driving element. The time of maximum reverse acceleration occurs at the time of maximum forward displacement .
- a catheter system 10 comprising a catheter 12 constructed in accordance with the principles of the present invention and a power supply 14 is illustrated.
- the catheter 12 includes a catheter body 16 having a distal end 18 and a proximal end 20, a proximal housing 22 having a fluid infusion port 24, and a guidewire port 26.
- the catheter 12 includes at least a single lumen 28 extending from the proximal end 20 to the distal end 18 and connected to both the fluid infusion port 24 and the guidewire port 26.
- the catheter 12 will have at least a second lumen (not illustrated) for accommodating wires (separate from the guidewire/fluid infusion lumen) .
- a cable 30 extends from the proximal end 20 of the catheter body 16 (typically through the lumen 28) and includes a connector 32 which may be removably attached to the power supply 14.
- the power supply 14 will be selected to drive the magnetostrictive driver at a about preselected frequency.
- the power supply 14 will be selected to provide an alternating current source for connection to the magnetostrictive driver.
- the drive frequency of the linear element of the magnetostrictive driver will depend principally on the resonant structure of the driver which is determined by the mass of the interface member and the elastic modulus of the spring element and of the drive element.
- the power supply 14 will be selected to operate at a frequency or frequencies consistent with the resonant frequency of the catheter itself.
- the operational range is typically from 10 kHz to 300 kHz, preferably from 20 kHz to 80 kHz.
- the power supply 14 may comprise a conventional signal generator, such as those commercially available from suppliers such as Hewlett-Packard, Palo Alto, California, and Tektronics, Portland, Oregon, and a power amplifier, such as those commercially available from suppliers such as ENI, Rochester, New York, and Krohn-Hite Corporation, Avon,
- the power supply might comprise custom signal generator and power amplifier circuits with tracking circuits to maintain the driving frequency at the catheter resonant frequency as the resonant frequency drifts due to thermally induced material variations.
- the magnetostrictive driver assembly 40 includes a tubular, linear element 42, disposed between a tail mass 44 and an interface member 46.
- the tail mass 44 and interface member 46 are joined by a tubular spring element 48, where the interface member 46 is shown to be integrally formed with the spring element 48.
- Such integral construction is not a requirement of the present invention and the interface member 46 could be attached to a separate spring element in a variety of conventional manners, such as using threads, welding, or the like.
- the proximal end at the spring element 48 is shown to be threadably attached to the tail mass.
- the attachment could be achieved by a variety of other techniques, again including welding, or the like.
- the spring force of the spring element 48 and mass of the interface member 46 are selected to provide for resonant operation of the assembly 40, as generally described above.
- the tail mass 44 will be secured directly to the proximal end of the catheter body 16, using adhesives, heat fusion, or other conventional techniques.
- a magnetic drive coil 50 will be disposed concentrically about the linear element 42, preferably overlapping the linear element 42 at both the proximal and distal ends. As illustrated, the coil 50 is embedded in the polymeric matrix of the catheter body 16. It would also be possible to provide the coil as a separate component apart from the catheter body. Referring now to Figs. 4 and 5, an alternative embodiment of the magnetostrictive driver assembly of the present invention will be described.
- the assembly 60 comprises a tail mass 62, an interface member 64, a linear element 66, and a drive coil 68.
- the interface member 64 is configured to provide both a first region 70 which extends laterally over the distal end of the catheter and a second region 72 which extends axially over a lateral surface of the catheter body.
- the linear member 66 is disposed between a first abutment member 76 which is formed integrally with the interface member 64 and a second abutment member 78 which is formed as part of the tail mass 62.
- the abutment members help assure that the drive coil 68 extends substantially beyond both the proximal and distal ends of the linear element 66. Such extensions help assure the uniformity of the magnetic field which is applied.
- the linear element 66 could be formed as a tube with a lumen suitable for receiving a guidewire, providing fluid delivery, and the like. In such cases, the tail mass 62 and interface member 64 would be provided with corresponding, coaxial lumens .
- a catheter 12 for directly engaging a region of thrombus T in a diseased blood vessel BV having a region of plaque is illustrated.
- the forwardly disposed interface surface of interface member 44 is advanced through the lumen of the blood vessel in a conventional manner until it engages the thrombus T.
- the resonantly vibrating assembly will then be activated (by applying an alternating current to drive coil 50) to cause longitudinal vibration of the interface member 4 .
- the interface surface of the interface member in turn, will transmit the vibrations directly into the thrombus T, resulting in mechanical disruption of the thrombus and clot.
- a thrombolytic or fibrinolytic agent may be delivered through the catheter 12 and released into a region proximal to the thrombus T, either before, during or after the mechanical disruption.
- the ultrasonic energy will be transmitted while the treatment agent is being released to enhance penetration of the agent into the thrombus T.
- FIG. 7 An alternative treatment method employing the catheter 12 of Figs. 4 and 5 is illustrated in Fig. 7.
- a sleeve catheter 90 is disposed over the catheter 12, and an anti-thrombogenic treatment agent is delivered to a target site TS within a blood vessel BV through an annular lumen defined between the sleeve and catheter 12, as indicated by arrows 91.
- the interface member 64 is oscillated, as described previously. The vibration will enhance penetration of the agent into the wall of the blood vessel BV.
- This method would be equally suitable for delivering drugs into other body lumens.
- Use of the sleeve catheter 90 for delivering drugs is illustrated as an alternative to delivering the drugs through the lumen of the catheter 12 itself.
- the sleeve catheter 90 could have been used in the method of Fig. 6.
- the lumen of catheter 12 could have been used to deliver the anti- thrombogenic agent in the method of Fig. 7.
- the interface member 64 results in transverse waves 93 emanating radially from a lateral surface thereof as well as longitudinal waves 95 emanating forwardly from the distal end of the catheter. Such wave patterns are particularly advantageous for enhancing drug penetration into the luminal wall.
- an annular air gap (not shown) could be left around the driver 66.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU12748/97A AU1274897A (en) | 1995-11-30 | 1996-11-27 | Apparatus and methods for vibratory intraluminal therapy employing magentostrictive transducers |
US09/077,251 US6221038B1 (en) | 1996-11-27 | 1996-11-27 | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/566,740 | 1995-11-30 | ||
US08/566,740 US5728062A (en) | 1995-11-30 | 1995-11-30 | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997019722A1 true WO1997019722A1 (en) | 1997-06-05 |
Family
ID=24264166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/018991 WO1997019722A1 (en) | 1995-11-30 | 1996-11-27 | Apparatus and methods for vibratory intraluminal therapy employing magentostrictive transducers |
Country Status (3)
Country | Link |
---|---|
US (1) | US5728062A (en) |
AU (1) | AU1274897A (en) |
WO (1) | WO1997019722A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008089770A1 (en) * | 2007-01-22 | 2008-07-31 | Coloplast A/S | Oscillating catheter |
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6113570A (en) * | 1994-09-09 | 2000-09-05 | Coraje, Inc. | Method of removing thrombosis in fistulae |
US6221038B1 (en) * | 1996-11-27 | 2001-04-24 | Pharmasonics, Inc. | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
US6723063B1 (en) | 1998-06-29 | 2004-04-20 | Ekos Corporation | Sheath for use with an ultrasound element |
US6582392B1 (en) | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6012457A (en) * | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
US6024740A (en) * | 1997-07-08 | 2000-02-15 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6514249B1 (en) | 1997-07-08 | 2003-02-04 | Atrionix, Inc. | Positioning system and method for orienting an ablation element within a pulmonary vein ostium |
US6652515B1 (en) * | 1997-07-08 | 2003-11-25 | Atrionix, Inc. | Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall |
US6500174B1 (en) * | 1997-07-08 | 2002-12-31 | Atrionix, Inc. | Circumferential ablation device assembly and methods of use and manufacture providing an ablative circumferential band along an expandable member |
US6997925B2 (en) * | 1997-07-08 | 2006-02-14 | Atrionx, Inc. | Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall |
US6117101A (en) * | 1997-07-08 | 2000-09-12 | The Regents Of The University Of California | Circumferential ablation device assembly |
AU2023199A (en) * | 1997-12-31 | 1999-07-19 | Pharmasonics, Inc. | Methods, systems, and kits for intravascular nucleic acid delivery |
US6794369B2 (en) | 1997-12-31 | 2004-09-21 | Pharmasonics | Methods, systems, and kits for intravascular nucleic acid delivery |
WO2000000252A1 (en) * | 1998-06-30 | 2000-01-06 | Origin Medsystems, Inc. | Apparatus and method for inducing vibrations in a living body |
AU1128600A (en) | 1998-11-20 | 2000-06-13 | Joie P. Jones | Methods for selectively dissolving and removing materials using ultra-high frequency ultrasound |
US6607502B1 (en) | 1998-11-25 | 2003-08-19 | Atrionix, Inc. | Apparatus and method incorporating an ultrasound transducer onto a delivery member |
US8506519B2 (en) | 1999-02-16 | 2013-08-13 | Flowcardia, Inc. | Pre-shaped therapeutic catheter |
US6855123B2 (en) | 2002-08-02 | 2005-02-15 | Flow Cardia, Inc. | Therapeutic ultrasound system |
US6758830B1 (en) * | 1999-05-11 | 2004-07-06 | Atrionix, Inc. | Catheter positioning system |
IL131623A0 (en) * | 1999-08-27 | 2001-01-28 | Dan Weiss | Apparatus to couple ultrasonic energy to catheters and other transdermal medical devices |
US20030065263A1 (en) * | 1999-10-05 | 2003-04-03 | Omnisonics Medical Technologies, Inc. | Ultrasonic probe device with rapid attachment and detachment means having a line contact collet |
US20040097996A1 (en) | 1999-10-05 | 2004-05-20 | Omnisonics Medical Technologies, Inc. | Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode |
US6551337B1 (en) * | 1999-10-05 | 2003-04-22 | Omnisonics Medical Technologies, Inc. | Ultrasonic medical device operating in a transverse mode |
US20050096669A1 (en) * | 1999-10-05 | 2005-05-05 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic medical device to treat coronary thrombus bearing lesions |
US20050119679A1 (en) * | 1999-10-05 | 2005-06-02 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic medical device to treat chronic total occlusions |
US6733451B2 (en) | 1999-10-05 | 2004-05-11 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic probe used with a pharmacological agent |
US20040249401A1 (en) * | 1999-10-05 | 2004-12-09 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic medical device with a non-compliant balloon |
US20040158150A1 (en) * | 1999-10-05 | 2004-08-12 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic medical device for tissue remodeling |
US6660013B2 (en) | 1999-10-05 | 2003-12-09 | Omnisonics Medical Technologies, Inc. | Apparatus for removing plaque from blood vessels using ultrasonic energy |
US20050043629A1 (en) * | 1999-10-05 | 2005-02-24 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic medical device having a probe with a small proximal end |
US20050043753A1 (en) * | 1999-10-05 | 2005-02-24 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic medical device to treat peripheral artery disease |
US6652547B2 (en) | 1999-10-05 | 2003-11-25 | Omnisonics Medical Technologies, Inc. | Apparatus and method of removing occlusions using ultrasonic medical device operating in a transverse mode |
US6695781B2 (en) | 1999-10-05 | 2004-02-24 | Omnisonics Medical Technologies, Inc. | Ultrasonic medical device for tissue remodeling |
US6695782B2 (en) | 1999-10-05 | 2004-02-24 | Omnisonics Medical Technologies, Inc. | Ultrasonic probe device with rapid attachment and detachment means |
US20030236539A1 (en) * | 1999-10-05 | 2003-12-25 | Omnisonics Medical Technologies, Inc. | Apparatus and method for using an ultrasonic probe to clear a vascular access device |
US6461383B1 (en) | 1999-12-30 | 2002-10-08 | Advanced Cardiovascular Systems, Inc. | Ultrasonic catheter vascular stent system and method |
EP1296598B1 (en) * | 2000-05-16 | 2007-11-14 | Atrionix, Inc. | Apparatus incorporating an ultrasound transducer on a delivery member |
AU6682401A (en) | 2000-06-13 | 2001-12-24 | Atrionix Inc | Surgical ablation probe for forming a circumferential lesion |
RU2160138C1 (en) * | 2000-07-10 | 2000-12-10 | Закрытое акционерное общество "ЭКОИНВЕНТ" | Method and device for therapeutic influence on biologic tissues by ultrasonic field |
US20060036191A1 (en) * | 2000-07-10 | 2006-02-16 | Naraykin Oleg S | Ultrasonic system for treatment of otolaryngologic diseases and ultrasonic instrument for these purposes and ultrasonic otolaryngologic set. |
US20060036190A1 (en) * | 2000-07-10 | 2006-02-16 | Naraikin Oleg S | Ultrasonic system for treatment of gynecologic diseases and ultrasonic instrument for these purposes and ultrasonic gynecologic set |
US20060036192A1 (en) * | 2000-07-10 | 2006-02-16 | Naraikin Oleg S | Ultrasonic system for treatment of urologic diseases and ultrasonic instrument for these purposes and ultrasonic urologic set |
US6416540B1 (en) | 2000-11-01 | 2002-07-09 | Sandip V. Mathur | Magnetically actuated cleanable stent and method |
US20030050692A1 (en) * | 2000-12-22 | 2003-03-13 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US6939375B2 (en) | 2000-12-22 | 2005-09-06 | Avantac Vascular Corporation | Apparatus and methods for controlled substance delivery from implanted prostheses |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US20050203612A1 (en) * | 2000-12-22 | 2005-09-15 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
US7077859B2 (en) * | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US7083642B2 (en) * | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US20030033007A1 (en) * | 2000-12-22 | 2003-02-13 | Avantec Vascular Corporation | Methods and devices for delivery of therapeutic capable agents with variable release profile |
US20050125054A1 (en) * | 2000-12-22 | 2005-06-09 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
US6489695B1 (en) * | 2001-01-24 | 2002-12-03 | The United States Of America As Represented By The Secretary Of The Navy | Efficiency maximized conversion of electrical to mechanical energy by magnetostrictive transduction |
US20030032898A1 (en) | 2001-05-29 | 2003-02-13 | Inder Raj. S. Makin | Method for aiming ultrasound for medical treatment |
US7846096B2 (en) | 2001-05-29 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Method for monitoring of medical treatment using pulse-echo ultrasound |
US7211044B2 (en) * | 2001-05-29 | 2007-05-01 | Ethicon Endo-Surgery, Inc. | Method for mapping temperature rise using pulse-echo ultrasound |
ES2278952T3 (en) * | 2001-07-26 | 2007-08-16 | Avantec Vascular Corporation | DEVICES FOR MANAGING THERAPEUTIC AGENTS WITH VARIABLE LIBERATION PROFILE. |
DE60209799T2 (en) | 2001-12-03 | 2007-01-25 | Ekos Corp., Bothell | CATHETER WITH SEVERAL ULTRASOUND EMITTING PARTS |
DE60213457T2 (en) * | 2001-12-03 | 2007-10-18 | Ekos Corp., Bothell | ULTRASONIC CATHETER FOR SMALL VESSELS |
AU2003209287A1 (en) | 2002-01-15 | 2003-07-30 | The Regents Of The University Of California | System and method providing directional ultrasound therapy to skeletal joints |
US7819826B2 (en) * | 2002-01-23 | 2010-10-26 | The Regents Of The University Of California | Implantable thermal treatment method and apparatus |
CN101717410B (en) | 2002-02-01 | 2015-04-29 | 阿里亚德医药股份有限公司 | Phosphorus-containing compounds & uses thereof |
WO2003068047A2 (en) * | 2002-02-11 | 2003-08-21 | Gold - T Tech, Inc. | Method for preventing thrombus formation |
US20040068189A1 (en) * | 2002-02-28 | 2004-04-08 | Wilson Richard R. | Ultrasound catheter with embedded conductors |
US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
US20040019266A1 (en) * | 2002-07-29 | 2004-01-29 | Omnisonics Medical Technologies, Inc. | Apparatus and method for radiopaque coating for an ultrasonic medical device |
US9955994B2 (en) | 2002-08-02 | 2018-05-01 | Flowcardia, Inc. | Ultrasound catheter having protective feature against breakage |
US8133236B2 (en) | 2006-11-07 | 2012-03-13 | Flowcardia, Inc. | Ultrasound catheter having protective feature against breakage |
US7220233B2 (en) * | 2003-04-08 | 2007-05-22 | Flowcardia, Inc. | Ultrasound catheter devices and methods |
US7604608B2 (en) * | 2003-01-14 | 2009-10-20 | Flowcardia, Inc. | Ultrasound catheter and methods for making and using same |
US7137963B2 (en) * | 2002-08-26 | 2006-11-21 | Flowcardia, Inc. | Ultrasound catheter for disrupting blood vessel obstructions |
US6942677B2 (en) | 2003-02-26 | 2005-09-13 | Flowcardia, Inc. | Ultrasound catheter apparatus |
US7335180B2 (en) | 2003-11-24 | 2008-02-26 | Flowcardia, Inc. | Steerable ultrasound catheter |
US6786202B2 (en) * | 2002-09-24 | 2004-09-07 | Caterpillar Inc | Hydraulic pump circuit |
US6907884B2 (en) | 2002-09-30 | 2005-06-21 | Depay Acromed, Inc. | Method of straddling an intraosseous nerve |
US8613744B2 (en) * | 2002-09-30 | 2013-12-24 | Relievant Medsystems, Inc. | Systems and methods for navigating an instrument through bone |
US8361067B2 (en) | 2002-09-30 | 2013-01-29 | Relievant Medsystems, Inc. | Methods of therapeutically heating a vertebral body to treat back pain |
US8808284B2 (en) * | 2008-09-26 | 2014-08-19 | Relievant Medsystems, Inc. | Systems for navigating an instrument through bone |
US7258690B2 (en) | 2003-03-28 | 2007-08-21 | Relievant Medsystems, Inc. | Windowed thermal ablation probe |
US20040176686A1 (en) * | 2002-12-23 | 2004-09-09 | Omnisonics Medical Technologies, Inc. | Apparatus and method for ultrasonic medical device with improved visibility in imaging procedures |
US6730048B1 (en) | 2002-12-23 | 2004-05-04 | Omnisonics Medical Technologies, Inc. | Apparatus and method for ultrasonic medical device with improved visibility in imaging procedures |
EP1583569A4 (en) * | 2003-01-03 | 2009-05-06 | Ekos Corp | Ultrasonic catheter with axial energy field |
US7374551B2 (en) * | 2003-02-19 | 2008-05-20 | Pittsburgh Plastic Surgery Research Associates | Minimally invasive fat cavitation method |
US8083707B2 (en) | 2003-04-17 | 2011-12-27 | Tosaya Carol A | Non-contact damage-free ultrasonic cleaning of implanted or natural structures having moving parts and located in a living body |
US7344509B2 (en) * | 2003-04-17 | 2008-03-18 | Kullervo Hynynen | Shear mode therapeutic ultrasound |
EP1619995A2 (en) * | 2003-04-22 | 2006-02-01 | Ekos Corporation | Ultrasound enhanced central venous catheter |
US20040230116A1 (en) * | 2003-05-12 | 2004-11-18 | Pharmasonics, Inc. | Method and apparatus for detection of ultrasound transducer failure in catheter systems |
US20050059993A1 (en) * | 2003-09-17 | 2005-03-17 | Kamal Ramzipoor | Embolectomy device |
US7758510B2 (en) | 2003-09-19 | 2010-07-20 | Flowcardia, Inc. | Connector for securing ultrasound catheter to transducer |
US20060058708A1 (en) * | 2003-12-24 | 2006-03-16 | Gill Heart | Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue |
US7491213B2 (en) * | 2004-01-13 | 2009-02-17 | Boston Scientific Scimed, Inc. | Catheter shaft having distal support |
CA2553165A1 (en) | 2004-01-29 | 2005-08-11 | Ekos Corporation | Method and apparatus for detecting vascular conditions with a catheter |
US7201737B2 (en) * | 2004-01-29 | 2007-04-10 | Ekos Corporation | Treatment of vascular occlusions using elevated temperatures |
US7794414B2 (en) | 2004-02-09 | 2010-09-14 | Emigrant Bank, N.A. | Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes |
US7247141B2 (en) | 2004-03-08 | 2007-07-24 | Ethicon Endo-Surgery, Inc. | Intra-cavitary ultrasound medical system and method |
US20050228286A1 (en) * | 2004-04-07 | 2005-10-13 | Messerly Jeffrey D | Medical system having a rotatable ultrasound source and a piercing tip |
US20050240123A1 (en) * | 2004-04-14 | 2005-10-27 | Mast T D | Ultrasound medical treatment system and method |
US20050240105A1 (en) * | 2004-04-14 | 2005-10-27 | Mast T D | Method for reducing electronic artifacts in ultrasound imaging |
US20050240124A1 (en) * | 2004-04-15 | 2005-10-27 | Mast T D | Ultrasound medical treatment system and method |
US20050234438A1 (en) * | 2004-04-15 | 2005-10-20 | Mast T D | Ultrasound medical treatment system and method |
US7494467B2 (en) * | 2004-04-16 | 2009-02-24 | Ethicon Endo-Surgery, Inc. | Medical system having multiple ultrasound transducers or an ultrasound transducer and an RF electrode |
US20050256405A1 (en) * | 2004-05-17 | 2005-11-17 | Makin Inder Raj S | Ultrasound-based procedure for uterine medical treatment |
US7883468B2 (en) * | 2004-05-18 | 2011-02-08 | Ethicon Endo-Surgery, Inc. | Medical system having an ultrasound source and an acoustic coupling medium |
US7951095B2 (en) * | 2004-05-20 | 2011-05-31 | Ethicon Endo-Surgery, Inc. | Ultrasound medical system |
US20050261587A1 (en) * | 2004-05-20 | 2005-11-24 | Makin Inder R S | Ultrasound medical system and method |
US7695436B2 (en) * | 2004-05-21 | 2010-04-13 | Ethicon Endo-Surgery, Inc. | Transmit apodization of an ultrasound transducer array |
US20050261588A1 (en) * | 2004-05-21 | 2005-11-24 | Makin Inder Raj S | Ultrasound medical system |
US7473250B2 (en) * | 2004-05-21 | 2009-01-06 | Ethicon Endo-Surgery, Inc. | Ultrasound medical system and method |
US7806839B2 (en) * | 2004-06-14 | 2010-10-05 | Ethicon Endo-Surgery, Inc. | System and method for ultrasound therapy using grating lobes |
US7197354B2 (en) * | 2004-06-21 | 2007-03-27 | Mediguide Ltd. | System for determining the position and orientation of a catheter |
US8409099B2 (en) * | 2004-08-26 | 2013-04-02 | Insightec Ltd. | Focused ultrasound system for surrounding a body tissue mass and treatment method |
US7540852B2 (en) | 2004-08-26 | 2009-06-02 | Flowcardia, Inc. | Ultrasound catheter devices and methods |
US7833221B2 (en) * | 2004-10-22 | 2010-11-16 | Ethicon Endo-Surgery, Inc. | System and method for treatment of tissue using the tissue as a fiducial |
US7452357B2 (en) * | 2004-10-22 | 2008-11-18 | Ethicon Endo-Surgery, Inc. | System and method for planning treatment of tissue |
US20060089626A1 (en) * | 2004-10-22 | 2006-04-27 | Vlegele James W | Surgical device guide for use with an imaging system |
WO2006049607A1 (en) * | 2004-10-28 | 2006-05-11 | Omnisonics Medical Technologies, Inc. | Apparatus and method for an ultrasonic medical device to treat chronic total occlusions |
US20060184070A1 (en) * | 2004-11-12 | 2006-08-17 | Hansmann Douglas R | External ultrasonic therapy |
KR100714682B1 (en) * | 2004-12-02 | 2007-05-04 | 삼성전자주식회사 | File system path processing device and method thereof |
US20060173387A1 (en) * | 2004-12-10 | 2006-08-03 | Douglas Hansmann | Externally enhanced ultrasonic therapy |
US8287583B2 (en) | 2005-01-10 | 2012-10-16 | Taheri Laduca Llc | Apparatus and method for deploying an implantable device within the body |
US20070150051A1 (en) * | 2005-01-10 | 2007-06-28 | Duke Fiduciary, Llc | Vascular implants and methods of fabricating the same |
US8221343B2 (en) | 2005-01-20 | 2012-07-17 | Flowcardia, Inc. | Vibrational catheter devices and methods for making same |
US8932208B2 (en) * | 2005-05-26 | 2015-01-13 | Maquet Cardiovascular Llc | Apparatus and methods for performing minimally-invasive surgical procedures |
US20060270900A1 (en) * | 2005-05-26 | 2006-11-30 | Chin Albert K | Apparatus and methods for performing ablation |
US20070016184A1 (en) * | 2005-07-14 | 2007-01-18 | Ethicon Endo-Surgery, Inc. | Medical-treatment electrode assembly and method for medical treatment |
EP1960993B1 (en) * | 2005-11-23 | 2016-11-02 | Insightec-Image Guided Treatment, Ltd. | Hierarchical switching in ultra-high density ultrasound array |
US20070185479A1 (en) * | 2006-02-06 | 2007-08-09 | Liming Lau | Methods and devices for performing ablation and assessing efficacy thereof |
US20070225697A1 (en) * | 2006-03-23 | 2007-09-27 | Ketan Shroff | Apparatus and methods for cardiac ablation |
US9282984B2 (en) * | 2006-04-05 | 2016-03-15 | Flowcardia, Inc. | Therapeutic ultrasound system |
WO2007127176A2 (en) | 2006-04-24 | 2007-11-08 | Ekos Corporation | Ultrasound therapy system |
US20100030076A1 (en) * | 2006-08-01 | 2010-02-04 | Kobi Vortman | Systems and Methods for Simultaneously Treating Multiple Target Sites |
US20090221955A1 (en) * | 2006-08-08 | 2009-09-03 | Bacoustics, Llc | Ablative ultrasonic-cryogenic methods |
US20080039727A1 (en) * | 2006-08-08 | 2008-02-14 | Eilaz Babaev | Ablative Cardiac Catheter System |
US20080039879A1 (en) * | 2006-08-09 | 2008-02-14 | Chin Albert K | Devices and methods for atrial appendage exclusion |
US8192363B2 (en) * | 2006-10-27 | 2012-06-05 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
US8246643B2 (en) | 2006-11-07 | 2012-08-21 | Flowcardia, Inc. | Ultrasound catheter having improved distal end |
US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
ES2538110T3 (en) * | 2007-01-08 | 2015-06-17 | Ekos Corporation | Power parameters for ultrasonic catheter |
US9526642B2 (en) * | 2007-02-09 | 2016-12-27 | Taheri Laduca Llc | Vascular implants and methods of fabricating the same |
US9044568B2 (en) | 2007-06-22 | 2015-06-02 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
WO2009045265A1 (en) | 2007-10-05 | 2009-04-09 | Maquet Cardiovascular, Llc | Devices and methods for minimally-invasive surgical procedures |
US9095685B2 (en) * | 2008-01-23 | 2015-08-04 | Mediguide Ltd. | Sensor mounted flexible guidewire |
CA2650703C (en) | 2008-01-23 | 2016-10-04 | Mediguide Ltd. | Sensor mounted flexible guidewire |
US20090209986A1 (en) * | 2008-02-15 | 2009-08-20 | Stewart Michael C | Devices, Tools and Methods for Atrial Appendage Exclusion |
US10028753B2 (en) | 2008-09-26 | 2018-07-24 | Relievant Medsystems, Inc. | Spine treatment kits |
AU2009296474B2 (en) | 2008-09-26 | 2015-07-02 | Relievant Medsystems, Inc. | Systems and methods for navigating an instrument through bone |
US8425424B2 (en) * | 2008-11-19 | 2013-04-23 | Inightee Ltd. | Closed-loop clot lysis |
US8617073B2 (en) * | 2009-04-17 | 2013-12-31 | Insightec Ltd. | Focusing ultrasound into the brain through the skull by utilizing both longitudinal and shear waves |
US8226566B2 (en) | 2009-06-12 | 2012-07-24 | Flowcardia, Inc. | Device and method for vascular re-entry |
EP2448636B1 (en) | 2009-07-03 | 2014-06-18 | Ekos Corporation | Power parameters for ultrasonic catheter |
WO2011024074A2 (en) * | 2009-08-26 | 2011-03-03 | Insightec Ltd. | Asymmetric phased-array ultrasound transducer |
US20110082414A1 (en) * | 2009-10-06 | 2011-04-07 | Wallace Michael P | Ultrasound-enhanced stenosis therapy |
US9375223B2 (en) | 2009-10-06 | 2016-06-28 | Cardioprolific Inc. | Methods and devices for endovascular therapy |
US20110082534A1 (en) * | 2009-10-06 | 2011-04-07 | Wallace Michael P | Ultrasound-enhanced stenosis therapy |
US20110082396A1 (en) * | 2009-10-06 | 2011-04-07 | Wallace Michael P | Ultrasound-enhanced stenosis therapy |
US20110105960A1 (en) * | 2009-10-06 | 2011-05-05 | Wallace Michael P | Ultrasound-enhanced Stenosis therapy |
US11039845B2 (en) | 2009-10-06 | 2021-06-22 | Cardioprolific Inc. | Methods and devices for endovascular therapy |
US20130023897A1 (en) * | 2009-10-06 | 2013-01-24 | Michael P Wallace | Devices and Methods for Endovascular Therapies |
EP2489034B1 (en) | 2009-10-14 | 2016-11-30 | Insightec Ltd. | Mapping ultrasound transducers |
US8740835B2 (en) * | 2010-02-17 | 2014-06-03 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
US9852727B2 (en) | 2010-04-28 | 2017-12-26 | Insightec, Ltd. | Multi-segment ultrasound transducers |
US8932237B2 (en) | 2010-04-28 | 2015-01-13 | Insightec, Ltd. | Efficient ultrasound focusing |
CN103228224B (en) | 2010-08-27 | 2015-11-25 | Ekos公司 | Be used for the treatment of the method and apparatus of intracranial hemorrhage |
US11458290B2 (en) | 2011-05-11 | 2022-10-04 | Ekos Corporation | Ultrasound system |
US10390877B2 (en) | 2011-12-30 | 2019-08-27 | Relievant Medsystems, Inc. | Systems and methods for treating back pain |
WO2013109269A1 (en) | 2012-01-18 | 2013-07-25 | Bard Peripheral Vascular, Inc. | Vascular re-entry device |
US10238895B2 (en) | 2012-08-02 | 2019-03-26 | Flowcardia, Inc. | Ultrasound catheter system |
US10588691B2 (en) | 2012-09-12 | 2020-03-17 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
CA3093398C (en) | 2012-11-05 | 2022-05-24 | Relievant Medsystems, Inc. | Systems and methods for creating curved paths through bone and modulating nerves within the bone |
CA2902713C (en) | 2013-03-14 | 2021-06-01 | Ekos Corporation | Method and apparatus for drug delivery to a target site |
US9724151B2 (en) | 2013-08-08 | 2017-08-08 | Relievant Medsystems, Inc. | Modulating nerves within bone using bone fasteners |
US10092742B2 (en) | 2014-09-22 | 2018-10-09 | Ekos Corporation | Catheter system |
US9943314B2 (en) | 2015-04-14 | 2018-04-17 | Teleflex Innovations S.À.R.L. | Magnetically-driven delivery assembly and method |
WO2016201136A1 (en) | 2015-06-10 | 2016-12-15 | Ekos Corporation | Ultrasound catheter |
US20180140321A1 (en) | 2016-11-23 | 2018-05-24 | C. R. Bard, Inc. | Catheter With Retractable Sheath And Methods Thereof |
US11596726B2 (en) | 2016-12-17 | 2023-03-07 | C.R. Bard, Inc. | Ultrasound devices for removing clots from catheters and related methods |
US10758256B2 (en) | 2016-12-22 | 2020-09-01 | C. R. Bard, Inc. | Ultrasonic endovascular catheter |
US10582983B2 (en) | 2017-02-06 | 2020-03-10 | C. R. Bard, Inc. | Ultrasonic endovascular catheter with a controllable sheath |
MX2020003574A (en) * | 2017-09-29 | 2020-08-03 | Bard Inc C R | Apparatus and method for tracking a medical ultrasonic object. |
US20190159792A1 (en) * | 2017-11-27 | 2019-05-30 | Justin Panian | Ultrasound Vessel Preparation and Restenosis Therapy |
AU2020346827A1 (en) | 2019-09-12 | 2022-03-31 | Relievant Medsystems, Inc. | Systems and methods for tissue modulation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4838853A (en) * | 1987-02-05 | 1989-06-13 | Interventional Technologies Inc. | Apparatus for trimming meniscus |
US4978333A (en) * | 1988-12-20 | 1990-12-18 | Valleylab, Inc. | Resonator for surgical handpiece |
US5197946A (en) * | 1990-06-27 | 1993-03-30 | Shunro Tachibana | Injection instrument with ultrasonic oscillating element |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3433226A (en) * | 1965-07-21 | 1969-03-18 | Aeroprojects Inc | Vibratory catheterization apparatus and method of using |
US3565062A (en) * | 1968-06-13 | 1971-02-23 | Ultrasonic Systems | Ultrasonic method and apparatus for removing cholesterol and other deposits from blood vessels and the like |
DE2710049C2 (en) * | 1977-03-08 | 1985-03-07 | MEDTRONIC medizinisch-elektronische Gerätegesellschaft mbH, 6390 Usingen | Ultrasonic dental treatment device |
US4636195A (en) * | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
CA1237482A (en) * | 1984-03-09 | 1988-05-31 | Frank B. Stiles | Catheter for effecting removal of obstructions from a biological duct |
EP0189329A3 (en) * | 1985-01-25 | 1987-06-03 | Robert E. Fischell | A tunneling catheter system for transluminal arterial angioplasty |
US4698058A (en) * | 1985-10-15 | 1987-10-06 | Albert R. Greenfeld | Ultrasonic self-cleaning catheter system for indwelling drains and medication supply |
US4948587A (en) * | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
US4808153A (en) * | 1986-11-17 | 1989-02-28 | Ultramed Corporation | Device for removing plaque from arteries |
US4870953A (en) * | 1987-11-13 | 1989-10-03 | Donmicheal T Anthony | Intravascular ultrasonic catheter/probe and method for treating intravascular blockage |
US5163421A (en) * | 1988-01-22 | 1992-11-17 | Angiosonics, Inc. | In vivo ultrasonic system with angioplasty and ultrasonic contrast imaging |
US5371520A (en) * | 1988-04-28 | 1994-12-06 | Canon Kabushiki Kaisha | Ink jet recording apparatus with stable, high-speed droplet ejection |
US4920954A (en) * | 1988-08-05 | 1990-05-01 | Sonic Needle Corporation | Ultrasonic device for applying cavitation forces |
US5458631A (en) * | 1989-01-06 | 1995-10-17 | Xavier; Ravi | Implantable catheter with electrical pulse nerve stimulators and drug delivery system |
US4936281A (en) * | 1989-04-13 | 1990-06-26 | Everest Medical Corporation | Ultrasonically enhanced RF ablation catheter |
JPH0363041A (en) * | 1989-07-31 | 1991-03-19 | Olympus Optical Co Ltd | Ultrasonic therapeutic apparatus |
US5085662A (en) * | 1989-11-13 | 1992-02-04 | Scimed Life Systems, Inc. | Atherectomy catheter and related components |
US5344395A (en) * | 1989-11-13 | 1994-09-06 | Scimed Life Systems, Inc. | Apparatus for intravascular cavitation or delivery of low frequency mechanical energy |
ATE123658T1 (en) * | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | DEVICE FOR DISPENSING MEDICATIONS. |
US5279546A (en) * | 1990-06-27 | 1994-01-18 | Lake Region Manufacturing Company, Inc. | Thrombolysis catheter system |
US5269291A (en) * | 1990-12-10 | 1993-12-14 | Coraje, Inc. | Miniature ultrasonic transducer for plaque ablation |
US5447509A (en) * | 1991-01-11 | 1995-09-05 | Baxter International Inc. | Ultrasound catheter system having modulated output with feedback control |
US5304115A (en) * | 1991-01-11 | 1994-04-19 | Baxter International Inc. | Ultrasonic angioplasty device incorporating improved transmission member and ablation probe |
US5267954A (en) * | 1991-01-11 | 1993-12-07 | Baxter International Inc. | Ultra-sound catheter for removing obstructions from tubular anatomical structures such as blood vessels |
US5324255A (en) * | 1991-01-11 | 1994-06-28 | Baxter International Inc. | Angioplasty and ablative devices having onboard ultrasound components and devices and methods for utilizing ultrasound to treat or prevent vasopasm |
DE69215722T3 (en) * | 1991-03-22 | 2001-03-08 | Katsuro Tachibana | Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them |
US5458568A (en) * | 1991-05-24 | 1995-10-17 | Cortrak Medical, Inc. | Porous balloon for selective dilatation and drug delivery |
GB2258364A (en) * | 1991-07-30 | 1993-02-03 | Intravascular Res Ltd | Ultrasonic tranducer |
EP0611293B1 (en) * | 1991-11-04 | 1998-03-25 | Baxter International Inc. | Ultrasonic ablation device adapted for guidewire passage |
US5269297A (en) * | 1992-02-27 | 1993-12-14 | Angiosonics Inc. | Ultrasonic transmission apparatus |
US5380273A (en) * | 1992-05-19 | 1995-01-10 | Dubrul; Will R. | Vibrating catheter |
JPH07500523A (en) * | 1992-08-28 | 1995-01-19 | コートラック・メディカル・インコーポレーテッド | Polymer matrix drug delivery device and method |
US5318014A (en) * | 1992-09-14 | 1994-06-07 | Coraje, Inc. | Ultrasonic ablation/dissolution transducer |
US5362309A (en) * | 1992-09-14 | 1994-11-08 | Coraje, Inc. | Apparatus and method for enhanced intravascular phonophoresis including dissolution of intravascular blockage and concomitant inhibition of restenosis |
US5267985A (en) * | 1993-02-11 | 1993-12-07 | Trancell, Inc. | Drug delivery by multiple frequency phonophoresis |
SE505864C2 (en) * | 1993-03-19 | 1997-10-20 | Tetra Laval Holdings & Finance | Device for ultrasonic sealing |
US5462523A (en) * | 1993-05-18 | 1995-10-31 | Target Therapeutics, Inc. | Drug delivery system |
US5465725A (en) * | 1993-06-15 | 1995-11-14 | Hewlett Packard Company | Ultrasonic probe |
US5413107A (en) * | 1994-02-16 | 1995-05-09 | Tetrad Corporation | Ultrasonic probe having articulated structure and rotatable transducer head |
AU1889595A (en) * | 1994-03-07 | 1995-09-25 | Medisonic A/S | Apparatus for non-invasive tissue destruction by means of ultrasound |
-
1995
- 1995-11-30 US US08/566,740 patent/US5728062A/en not_active Expired - Fee Related
-
1996
- 1996-11-27 WO PCT/US1996/018991 patent/WO1997019722A1/en active Application Filing
- 1996-11-27 AU AU12748/97A patent/AU1274897A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4838853A (en) * | 1987-02-05 | 1989-06-13 | Interventional Technologies Inc. | Apparatus for trimming meniscus |
US4978333A (en) * | 1988-12-20 | 1990-12-18 | Valleylab, Inc. | Resonator for surgical handpiece |
US5197946A (en) * | 1990-06-27 | 1993-03-30 | Shunro Tachibana | Injection instrument with ultrasonic oscillating element |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008089770A1 (en) * | 2007-01-22 | 2008-07-31 | Coloplast A/S | Oscillating catheter |
Also Published As
Publication number | Publication date |
---|---|
US5728062A (en) | 1998-03-17 |
AU1274897A (en) | 1997-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5728062A (en) | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers | |
US6221038B1 (en) | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers | |
US5725494A (en) | Apparatus and methods for ultrasonically enhanced intraluminal therapy | |
US5735811A (en) | Apparatus and methods for ultrasonically enhanced fluid delivery | |
US6287272B1 (en) | Balloon catheters having ultrasonically driven interface surfaces and methods for their use | |
US6464660B2 (en) | Balloon catheters having ultrasonically driven interface surfaces and methods for their use | |
WO1997019645A9 (en) | Apparatus and methods for ultrasonically enhanced fluid delivery | |
US5931805A (en) | Catheters comprising bending transducers and methods for their use | |
US6024718A (en) | Intraluminal directed ultrasound delivery device | |
US6228046B1 (en) | Catheters comprising a plurality of oscillators and methods for their use | |
US6554846B2 (en) | Sonic burr | |
US20050096669A1 (en) | Apparatus and method for an ultrasonic medical device to treat coronary thrombus bearing lesions | |
US20050119679A1 (en) | Apparatus and method for an ultrasonic medical device to treat chronic total occlusions | |
US20050043753A1 (en) | Apparatus and method for an ultrasonic medical device to treat peripheral artery disease | |
JP2010221064A (en) | Ultrasound catheter for disrupting blood vessel obstructions | |
US20050256410A1 (en) | Apparatus and method for an ultrasonic probe capable of bending with aid of a balloon | |
US20050043626A1 (en) | Apparatus and method for an ultrasonic medical device engaging a flexible material | |
JP2023510453A (en) | Wires for intravascular devices | |
JP2009529372A (en) | Catheter and related systems and methods | |
AU2008361369B2 (en) | Micro-emulsifier for arterial thrombus removal | |
JP2007195599A (en) | Medical guide wire | |
WO2005115545A1 (en) | Ultrasonic probe capable of bending with aid of a balloon | |
JP5002303B2 (en) | Medical guidewire | |
WO2006041475A1 (en) | Apparatus and method for an ultrasonic medical device having a probe with a small proximal end | |
WO2006049600A1 (en) | Apparatus and method for an ultrasonic medical device to treat coronary thrombus bearing lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97520653 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09077251 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |